Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Lenalidomide
Teva B.V.
L04AX; L04AX04
Lenalidomide
5 milligram(s)
Capsule, hard
Other immunosuppressants; lenalidomide
Marketed
2019-05-03
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LENALIDOMIDE TEVA 2.5 MG HARD CAPSULES LENALIDOMIDE TEVA 5 MG HARD CAPSULES LENALIDOMIDE TEVA 7.5 MG HARD CAPSULES LENALIDOMIDE TEVA 10 MG HARD CAPSULES LENALIDOMIDE TEVA 15 MG HARD CAPSULES LENALIDOMIDE TEVA 20 MG HARD CAPSULES LENALIDOMIDE TEVA 25 MG HARD CAPSULES lenalidomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. WHAT LENALIDOMIDE TEVA IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LENALIDOMIDE TEVA 3. HOW TO TAKE LENALIDOMIDE TEVA 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE LENALIDOMIDE TEVA 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT LENALIDOMIDE TEVA IS AND WHAT IT IS USED FOR WHAT LENALIDOMIDE TEVA IS Lenalidomide Teva contains the active substance ‘lenalidomide’. This medicine belongs to a group of medicines which affect how your immune system works. WHAT LENALIDOMIDE TEVA IS USED FOR Lenalidomide Teva is used in adults for • Multiple myeloma • Myelodysplastic syndromes • Mantle cell lymphoma • Follicular lymphoma MULTIPLE MYELOMA Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys. Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘response’. Newly diagnosed multiple myeloma – in patients who hav Read the complete document
HealthProductsRegulatoryAuthority 01February2024 CRN00F28W Page1of53 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT LenalidomideTeva5mgHardCapsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Eachcapsulecontainslenalidomidehydrochloridehydratecorrespondingto2.5 mgoflenalidomide Excipientswithknowneffect: LenalidomideTeva2.5mghardcapsules: Eachcapsulecontains0.5mgofsodium. Forthefulllistofexcipients,seesection6.1. 3 PHARMACEUTICAL FORM Hardcapsule. Hard,non-transparentcapsules,size"4"(approximately14.3 mminlength),imprintedinblackwith '5'onwhitebodyandwith whitecap,containingoff-whitetopaleyelloworbeigepowderorcompressedpowder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Multiplemyeloma Lenalidomideasmonotherapyisindicatedforthemaintenancetreatmentofadultpatientswithnewlydiagnosedmultiple myelomawhohaveundergoneautologousstemcelltransplantation. Lenalidomideascombinationtherapywithdexamethasone,orbortezomibanddexamethasone,ormelphalanandprednisone (seesection4.2)isindicatedforthetreatmentofadultpatientswithpreviouslyuntreatedmultiplemyelomawhoarenot eligiblefortransplant. Lenalidomideincombinationwithdexamethasoneisindicatedforthetreatmentofmultiplemyelomainadultpatientswho havereceivedatleastonepriortherapy. Follicularlymphoma Lenalidomideincombinationwithrituximab(anti-CD20antibody)isindicatedforthetreatmentofadultpatientswith previouslytreatedfollicularlymphoma(Grade1–3a). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION LenalidomideTevatreatmentshouldbesupervisedbyaphysicianexperiencedintheuseofanti-cancertherapies. Forallindicationsdescribedbelow: Doseismodifiedbaseduponclinical Read the complete document